ArticleEuropean journal of medical research2025
Impact of anti-osteoporotic treatments on hyperlipidemia risk in osteoporosis patients: evidence from a population-based retrospective cohort study.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundIn this population-based retrospective cohort study, we investigated the relationship between osteoporosis and the risk of hyperlipidemia, the main risk factor for cardiovascular disease (CVD). Despite extensive research on both conditions, the association between osteoporosis and hyperlipidemia remains unclear, particularly in Asian populations.
methodsUsing information from Taiwan's Longitudinal Generation Tracking Database, we conducted a retrospective population-based cohort study spanning 2000-2021. Patients in the comparison cohort were chosen at random and frequency-matched in a 1:1 ratio based on age, sex, month, and year of the index date. Both cohorts were monitored from the index date until a new diagnosis of hyperlipidemia was established. Data on baseline characteristics, comorbidities, and prescription of anti-osteoporotic treatment (AOTs) were gathered.
resultsThe osteoporosis cohort consisted of 67,628 patients aged ≤ 34 years or older, diagnosed with osteoporosis, and without a history of hyperlipidemia. With a mean follow-up of 8.81 years and 9.78 years, respectively, the total incidence of hyperlipidemia was 36.7 (per 1000 person-years) for the osteoporosis cohort and 28.4 for the comparison cohort, after controlling for age, sex, and comorbidities. Without treatment, the hazard ratio (HR) for developing hyperlipidemia was 1.58 (95% confidence interval [CI], 1.54-1.62) for the osteoporosis cohort compared with the comparison cohort. The risk of hyperlipidemia was considerably reduced in patients with osteoporosis who received most types of AOTs [adjusted HR, ≤ 0.31] compared with those who did not receive any of these AOTs.
conclusionOur findings suggest a significant association between osteoporosis and increased risk of hyperlipidemia in Asian populations, and highlight the potential protective role of AOTs against hyperlipidemia. These insights could inform clinical strategies to manage patients with osteoporosis and mitigate their risk of CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.